Earnings Releases·Nov 9, 2026, 8:15 AM ET

Heron Therapeutics — Third Quarter 2026 Earnings Summary

Total net revenue declined 7.8% year-over-year to $35.3 million for the quarter and 5.9% to $107.6 million for the nine-month period, driven by a 22.2% drop in Oncology Supportive Care revenue offset by 22.5% growth in the Acute Care franchise.
Net loss narrowed significantly to $5.0 million ($0.03 per share) for the quarter compared to $17.5 million in the prior year, while Adjusted EBITDA improved to $3.7 million from $1.5 million.
The Company entered a definitive agreement for CorMedix Therapeutics to acquire substantially all of its assets, a transaction subject to stockholder approval and other closing conditions.
Full-year 2026 financial guidance was withdrawn in August 2026, with no new guidance provided at this time.
Liquidity remains constrained with $23.4 million in cash and short-term investments, while the company faces risks regarding going concern status, Nasdaq listing compliance, and debt covenant adherence pending the asset sale.